Fyodor, a Baltimore-based biotechnology company, announced today that the US National Science Foundation (NSF) has awarded the company a Small Business Innovation Research (SBIR) Phase 2 grant. The $729,000 funding will help accelerate Fyodor’s effort to develop and validate a noninvasive multi-disease urine-based diagnostic test for Acute Febrile Illness (AFI), enabling the differential clinical diagnosis of leading global health diseases like malaria, typhoid, dengue, and leptospirosis from a single urine specimen in patients with fever.
{iframe}http://www.fyodorbio.com/2013/09/fyodor-biotechnologies-awarded-sbir-phase-2-grant-to-develop-a-urine-based-multi-disease-test-for-acute-febrile-illness/{/iframe}